Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 7:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 796 matching trials from the live ClinicalTrials.gov search.
Conditions
Tetanus, Diphtheria, Pertussis, Measles, Polio
Interventions
Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus, Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
4 Years to 6 Years
Enrollment
3,372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
71
States / cities
Birmingham, Alabama • Pinson, Alabama • Trussville, Alabama + 60 more
Conditions
Soft Tissue Infections
Interventions
daptomycin (up to 14 days)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
12
States / cities
Torrance, California • Tampa, Florida • Augusta, Georgia + 9 more
Conditions
Staphylococcal Vaccine
Interventions
Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
3,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
234
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 89 more
Conditions
Meningococcal Meningitis, Tetanus, Diphtheria, Pertussis, Poliomyelitis
Interventions
Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
4 Years to 7 Years
Enrollment
882 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
26
States / cities
Little Rock, Arkansas • Boulder, Colorado • Atlanta, Georgia + 23 more
Conditions
Nontuberculous Mycobacterium Infection
Interventions
gNO
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Portland, Oregon • Charleston, South Carolina
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

NCT04493671
Conditions
Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
Interventions
TBAJ-876 suspension, Placebo suspension, TBAJ-876 100 mg tablet, TBAJ-876 25 mg tablet
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Completed Phase 1Phase 2 Interventional Results available

The ICON Study: Outcomes After FMT for Patients With IBD and CDI

NCT03106844
Conditions
Inflammatory Bowel Diseases, Clostridium Difficile Infection
Interventions
Fecal Microbiota Transplantation
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Clarithromycin, Zidovudine, Didanosine
Drug
Lead sponsor
Abbott
Industry
Eligibility
3 Months to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • Bethesda, Maryland
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Ethambutol hydrochloride, Clarithromycin, Clofazimine, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
16
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 12 more
Conditions
Staphylococcus
Interventions
Mupirocin Topical Ointment, Petroleum Jelly
Drug
Lead sponsor
Crouse Hospital
Other
Eligibility
Not listed
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Syracuse, New York
Conditions
Cystic Fibrosis
Interventions
Throat Swab
Procedure
Lead sponsor
Tufts Medical Center
Other
Eligibility
1 Day to 3 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Tuberculosis
Interventions
18F-Pretomanid PET/CT
Combination Product
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections, Pneumococcal Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
15
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Withdrawn No phase listed Observational

Tuberculosis Research Blood Bank

NCT00212498
Conditions
Tuberculosis
Interventions
Develop a bank of blood samples from patients infected with TB for future molecular genetics studies and serological studies
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
New York, New York
Conditions
Gram-Positive Bacterial Infections
Interventions
Telavancin, Vancomycin, nafcillin, oxacillin, or cloxacillin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Marietta, Georgia
Conditions
Clostridium Difficile Infection
Interventions
Vancomycin, Placebo
Drug · Other
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
1,294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
Dearborn, Michigan • Royal Oak, Michigan • Troy, Michigan
Conditions
Pneumococcal Disease
Interventions
PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
15 Months to 17 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
62
States / cities
Birmingham, Alabama • Guntersville, Alabama • Fair Oaks, California + 37 more
Conditions
Tuberculosis
Interventions
PNU-100480, Placebo, Linezolid
Drug
Lead sponsor
Sequella, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 3 Interventional Accepts healthy volunteers

StaphVAX Immunogenicity in Orthopedic Implant Patients

NCT00211926
Conditions
Staphylococcal Infections, Joint Prosthesis
Interventions
S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate, placebo
Biological
Lead sponsor
Nabi Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Norfolk, Virginia
Conditions
HIV Infections, Tuberculosis
Interventions
Isoniazid, Pyridoxine hydrochloride, Levofloxacin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 7 more
Completed No phase listed Observational Accepts healthy volunteers Results available

Postlicensure Observational Safety Study of 13vPnC Administered to Infants and Toddlers

NCT01128426
Conditions
Pneumococcal Disease
Interventions
No Intervention
Other
Lead sponsor
Pfizer
Industry
Eligibility
2 Months to 3 Years
Enrollment
53,902 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Oakland, California
Conditions
Staphylococcal Skin Infection
Interventions
Telavancin, Vancomycin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
New Orleans, Louisiana
Conditions
Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
Interventions
Not listed
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cystic Fibrosis, Pseudohypoaldosteronism, Nontuberculous Mycobacterial Infection, Chronic Granulomatous Disease, Primary Ciliary Dyskinesia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland